Abstract
Alzheimer’s Disease (AD) is characterized by progressive memory loss due to neurodegeneration that occurs mainly during aging. The accumulation of senescent cells has been related to aging. Furthermore, the expression of the variant ApoE ε4 is a critical risk factor for AD. Some events that occur in senescence, such as the secretion of pro-inflammatory molecules, and metabolic and epigenetic changes, in addition to the detection of ApoE4, may accelerate the progression of AD. Here, we discuss the implications of cellular senescence and the ApoE variants in AD. Molecular studies of these risk factors for AD may hence be pivotal to define new biomarkers and novel therapeutic strategies for this neurodegenerative pathology.
Keywords: Alzheimer, ApoE, senescence, aging, neurodegeneration, AD progression.
Graphical Abstract
CNS & Neurological Disorders - Drug Targets
Title:Cellular Senescence and ApoE4: Their Repercussions in Alzheimer’s Disease
Volume: 20 Issue: 9
Author(s): Angeles C. Tecalco-Cruz*, Jesús Zepeda-Cervantes, Lilia López-Canovas, Josué Oriando Ramírez-Jarquín, José Pedraza-Chaverrí and Alfredo Briones-Herrera
Affiliation:
- Posgrado en Ciencias Genomicas, Universidad Autonoma de la Ciudad de Mexico (UACM), Apdo, Postal 03100, Ciudad de Mexico,Mexico
Keywords: Alzheimer, ApoE, senescence, aging, neurodegeneration, AD progression.
Abstract: Alzheimer’s Disease (AD) is characterized by progressive memory loss due to neurodegeneration that occurs mainly during aging. The accumulation of senescent cells has been related to aging. Furthermore, the expression of the variant ApoE ε4 is a critical risk factor for AD. Some events that occur in senescence, such as the secretion of pro-inflammatory molecules, and metabolic and epigenetic changes, in addition to the detection of ApoE4, may accelerate the progression of AD. Here, we discuss the implications of cellular senescence and the ApoE variants in AD. Molecular studies of these risk factors for AD may hence be pivotal to define new biomarkers and novel therapeutic strategies for this neurodegenerative pathology.
Export Options
About this article
Cite this article as:
Tecalco-Cruz C. Angeles*, Zepeda-Cervantes Jesús, López-Canovas Lilia , Ramírez-Jarquín Oriando Josué, Pedraza-Chaverrí José and Briones-Herrera Alfredo , Cellular Senescence and ApoE4: Their Repercussions in Alzheimer’s Disease, CNS & Neurological Disorders - Drug Targets 2021; 20 (9) . https://dx.doi.org/10.2174/1871527320666210628102721
DOI https://dx.doi.org/10.2174/1871527320666210628102721 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effectivity of Long Antigen Exposition Dendritic Cell Therapy (LANEXDC<sup>®</sup>) in the Palliative Treatment of Pancreatic Cancer
Current Medicinal Chemistry Prediction of Gene Co-Expression by Quantifying Heterogeneous Features
Current Bioinformatics Nanoparticle-Delivered Quercetin for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Towards a Stratified Targeted Approach with Biologic Treatments in Rheumatoid Arthritis: Role of Synovial Pathobiology
Current Pharmaceutical Design Angiogenic and Vascular Modulation by Extracellular Matrix Cleavage Products
Current Pharmaceutical Design Molecular Probes for Malignant Melanoma Imaging
Current Pharmaceutical Biotechnology Bone Morphogenetic Proteins and its Receptors; Therapeutic Targets in Cancer Progression and Bone Metastasis?
Current Pharmaceutical Design Aminopeptidase N (APN/CD13) as a Target for Anti-Cancer Agent Design
Current Medicinal Chemistry “Non-Taxifolin” Derived Flavonolignans: Phytochemistry and Biology
Current Pharmaceutical Design Editorial (Thematic Issue: Cytochrome P450 for Cancer Prevention and Therapy)
Anti-Cancer Agents in Medicinal Chemistry Infection and Malignancy Risk in Patients Treated with TNF Inhibitors for Immune-Mediated Inflammatory Diseases
Current Drug Safety Drug Targeting Strategies in Cancer Treatment: An Overview
Mini-Reviews in Medicinal Chemistry Overview of Mechanisms of Cancer Stem Cell Drug Resistance
Current Signal Transduction Therapy In Vitro and In Vivo Evaluation of [99mTc(CO)3]-Radiolabeled ErbB-2-Targeting Peptides for Breast Carcinoma Imaging
Current Radiopharmaceuticals γ δ T Cells and Dendritic Cells: Close Partners and Biological Adjuvants for New Therapies
Current Molecular Medicine The SCF-type E3 Ubiquitin Ligases as Cancer Targets
Current Cancer Drug Targets Endogenous Retroelements in Cellular Senescence and Related Pathogenic Processes: Promising Drug Targets in Age-Related Diseases
Current Drug Targets ABC Transporters in the Development of Multidrug Resistance in Cancer Therapy
Current Pharmaceutical Design Use of Anti-Cancer Drugs, Mitocans, to Enhance the Immune Responses against Tumors
Current Pharmaceutical Biotechnology Dietary Polyphenols for Prostate Cancer Therapy
Current Bioactive Compounds